首页 > 最新文献

Prostaglandins & other lipid mediators最新文献

英文 中文
The Dual Role of 25-Hydroxycholesterol in Atherosclerosis: From Homeostatic Regulation to Plaque Instability. 25-羟基胆固醇在动脉粥样硬化中的双重作用:从稳态调节到斑块不稳定。
IF 2.5 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-03-05 DOI: 10.1016/j.prostaglandins.2026.107065
Reyhane Ghayour Vatanparast, Sahar Ghoflchi, Mahdieh Aliyari, Hadiseh Mohammadi, Mahla Palizkaran Yazdi, Hossein Hosseini

Background: Atherosclerosis is a chronic inflammatory pathology driven by lipid accumulation and immune activation. 25-Hydroxycholesterol (25-HC), an oxysterol synthesized by cholesterol 25-hydroxylase (CH25H) in response to inflammatory stimuli, has emerged as a potent bioactive lipid mediator at the nexus of cholesterol homeostasis and innate immunity.

Objective: Unlike broader reviews on oxysterols, this article synthesizes the multifaceted and context-dependent roles of 25-HC in atherogenesis. We aim to elucidate its specific mechanistic actions across endothelial cells, macrophages, and vascular smooth muscle cells (VSMCs), emphasizing its dual nature and potential as a therapeutic target.

Methods: We conducted a comprehensive review of the literature to integrate mechanistic insights into 25-HC signaling pathways, their regulation by specific transcription factors, and their impact on vascular pathology.

Results: 25-HC exhibits a distinct biphasic dose-response. At physiological concentrations, it maintains lipid homeostasis through suppression of SREBP processing and activation of LXR signaling. However, supraphysiological accumulation induces oxidative stress, mitochondrial dysfunction, and a coordinated activation of apoptosis and autophagy, ultimately precipitating cytotoxicity. Mechanistically, 25-HC disrupts membrane lipid rafts and activates the RIG-I/MAVS axis to drive pro-inflammatory cytokine secretion (e.g., IL-8). Within the plaque microenvironment, it impairs macrophage efferocytosis by downregulating MerTK and promotes VSMC proliferation and migration via PI3K/AKT pathways. Conversely, the transcription factor KLF4 and enzymatic sulfation by SULT2B1b act as critical protective checkpoints against 25-HC-mediated toxicity.

Conclusion: 25-HC is not merely a biochemical byproduct but a functional determinant of plaque instability. Its impact is strictly governed by local concentration gradients and metabolic regulation. Future therapeutic strategies should focus on modulating the CH25H/KLF4 axis and promoting oxysterol sulfation to mitigate vascular inflammation and prevent atherosclerosis progression.

背景:动脉粥样硬化是一种由脂质积累和免疫激活驱动的慢性炎症病理。25-羟基胆固醇(25-HC)是一种由胆固醇25-羟化酶(CH25H)在炎症刺激下合成的氧甾醇,已成为一种有效的生物活性脂质介质,在胆固醇稳态和先天免疫之间起着重要作用。目的:与对氧甾醇的广泛综述不同,本文综合了25-HC在动脉粥样硬化发生中的多方面和环境依赖性作用。我们的目的是阐明其在内皮细胞、巨噬细胞和血管平滑肌细胞(VSMCs)中的特定机制作用,强调其双重性质和作为治疗靶点的潜力。方法:我们对文献进行了全面的回顾,以整合对25-HC信号通路的机制见解,特定转录因子对它们的调节,以及它们对血管病理的影响。结果:25-HC表现出明显的双相剂量反应。在生理浓度下,它通过抑制SREBP加工和激活LXR信号来维持脂质稳态。然而,超生理积累诱导氧化应激、线粒体功能障碍以及细胞凋亡和自噬的协同激活,最终导致细胞毒性。在机制上,25-HC破坏膜脂筏并激活RIG-I/MAVS轴以驱动促炎细胞因子分泌(如IL-8)。在斑块微环境中,它通过下调MerTK抑制巨噬细胞的efferocytosis,并通过PI3K/AKT通路促进VSMC的增殖和迁移。相反,转录因子KLF4和SULT2B1b的酶促磺化作用是对抗25- hc介导的毒性的关键保护性检查点。结论:25-HC不仅是一种生化副产物,而且是斑块不稳定性的功能决定因素。其影响严格受局部浓度梯度和代谢调节的支配。未来的治疗策略应该集中在调节CH25H/KLF4轴和促进氧甾醇硫酸化,以减轻血管炎症和防止动脉粥样硬化的进展。
{"title":"The Dual Role of 25-Hydroxycholesterol in Atherosclerosis: From Homeostatic Regulation to Plaque Instability.","authors":"Reyhane Ghayour Vatanparast, Sahar Ghoflchi, Mahdieh Aliyari, Hadiseh Mohammadi, Mahla Palizkaran Yazdi, Hossein Hosseini","doi":"10.1016/j.prostaglandins.2026.107065","DOIUrl":"https://doi.org/10.1016/j.prostaglandins.2026.107065","url":null,"abstract":"<p><strong>Background: </strong>Atherosclerosis is a chronic inflammatory pathology driven by lipid accumulation and immune activation. 25-Hydroxycholesterol (25-HC), an oxysterol synthesized by cholesterol 25-hydroxylase (CH25H) in response to inflammatory stimuli, has emerged as a potent bioactive lipid mediator at the nexus of cholesterol homeostasis and innate immunity.</p><p><strong>Objective: </strong>Unlike broader reviews on oxysterols, this article synthesizes the multifaceted and context-dependent roles of 25-HC in atherogenesis. We aim to elucidate its specific mechanistic actions across endothelial cells, macrophages, and vascular smooth muscle cells (VSMCs), emphasizing its dual nature and potential as a therapeutic target.</p><p><strong>Methods: </strong>We conducted a comprehensive review of the literature to integrate mechanistic insights into 25-HC signaling pathways, their regulation by specific transcription factors, and their impact on vascular pathology.</p><p><strong>Results: </strong>25-HC exhibits a distinct biphasic dose-response. At physiological concentrations, it maintains lipid homeostasis through suppression of SREBP processing and activation of LXR signaling. However, supraphysiological accumulation induces oxidative stress, mitochondrial dysfunction, and a coordinated activation of apoptosis and autophagy, ultimately precipitating cytotoxicity. Mechanistically, 25-HC disrupts membrane lipid rafts and activates the RIG-I/MAVS axis to drive pro-inflammatory cytokine secretion (e.g., IL-8). Within the plaque microenvironment, it impairs macrophage efferocytosis by downregulating MerTK and promotes VSMC proliferation and migration via PI3K/AKT pathways. Conversely, the transcription factor KLF4 and enzymatic sulfation by SULT2B1b act as critical protective checkpoints against 25-HC-mediated toxicity.</p><p><strong>Conclusion: </strong>25-HC is not merely a biochemical byproduct but a functional determinant of plaque instability. Its impact is strictly governed by local concentration gradients and metabolic regulation. Future therapeutic strategies should focus on modulating the CH25H/KLF4 axis and promoting oxysterol sulfation to mitigate vascular inflammation and prevent atherosclerosis progression.</p>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":" ","pages":"107065"},"PeriodicalIF":2.5,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147373244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The evolving landscape of lipid mediator research: Emerging findings and observations from the 19th Winter Eicosanoid conference 脂质介质研究的演变景观:来自第19届冬季类二十烷会议的新发现和观察。
IF 2.5 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-03-01 Epub Date: 2026-02-12 DOI: 10.1016/j.prostaglandins.2026.107062
Victor Garcia, Danielle Diegisser, Alexandra Wolf, Jonathan V. Pascale, Michal L. Schwartzman
{"title":"The evolving landscape of lipid mediator research: Emerging findings and observations from the 19th Winter Eicosanoid conference","authors":"Victor Garcia,&nbsp;Danielle Diegisser,&nbsp;Alexandra Wolf,&nbsp;Jonathan V. Pascale,&nbsp;Michal L. Schwartzman","doi":"10.1016/j.prostaglandins.2026.107062","DOIUrl":"10.1016/j.prostaglandins.2026.107062","url":null,"abstract":"","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"183 ","pages":"Article 107062"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146197913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wulingsan alleviates metabolic dysfunction-associated steatotic liver disease through regulating gut microbiota-bile acid axis 五灵散通过调节肠道菌群-胆汁酸轴缓解代谢功能障碍相关的脂肪变性肝病。
IF 2.5 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-03-01 Epub Date: 2026-03-08 DOI: 10.1016/j.prostaglandins.2026.107067
Junyu Luo , Xiaowen Jin , Mingyue Cui , Hanyu He , Jiabao Liao , Weibo Wen , Wenting Li , Yongjun Cao

Background

Metabolic dysfunction-associated Steatotic Liver Disease (MASLD) is closely linked to gut microbiota disorders and bile acid imbalance. Wulingsan (WLS) have shown promise in regulating these pathways, but its mechanism of action unclear. This study aimed to evaluate the therapeutic effect of WLS on the rat MASLD model from the perspectives of intestinal microbiota composition and bile acid homeostasis.

Methods

The MASLD model was induced by a high-fat diet (HFD) and treated with different doses of WLS. Body weight and serum lipid profiles were monitored, inflammation were assessed to ELISA and RT-qPCR. H&E staining to evaluate histopathological changes. The 16S rRNA sequencing and LC-MS/MS analysis of gut microbiota composition and bile acid profiles. The fecal microbiota transplantation (FMT) experiment verified the effect of WLS on the gut microbiota.

Results

WLS treatment reduces the body weight of MASLD rats, improves lipid indicators, and inhibits inflammation and liver damage. The results of the FMT experiment indicated that transplantation of fecal microbiota from WLS-treated donors regulated the gut microbial composition and restored bile acid metabolic homeostasis in recipient rats.

Discussion

This study demonstrates that WLS treats MASLD by modulating multiple pathological pathways. Its effects in improving lipid metabolism and reducing hepatic inflammation align with the pathophysiological mechanisms of MASLD, indicating direct hepatoprotective actions. WLS intervention significantly restored gut microbiota diversity, increased the proportion of beneficial bacteria, suppressed potentially harmful bacterial genera, and corrected dysbiosis. FMT experiments further confirmed that gut microbes play a crucial role in mediating the therapeutic benefits of WLS. When microbiota from WLS-treated donors were transplanted into recipient rats, significant improvements were observed in metabolic markers, hepatic histopathology, and bile acid homeostasis. Collectively, the data support that WLS improves MASLD through a multi-targeted strategy centered on the gut-liver axis.

Conclusion

WLS has an effective therapeutic effect on MASLD by improving lipid metabolism, reducing liver inflammation, reshaping the intestinal microbiota and normalizing bile acid homeostasis.
背景:代谢功能障碍相关的脂肪变性肝病(MASLD)与肠道菌群紊乱和胆汁酸失衡密切相关。五灵散在调节这些通路方面显示出良好的前景,但其作用机制尚不清楚。本研究旨在从肠道菌群组成和胆汁酸稳态的角度评价枸杞多糖对大鼠MASLD模型的治疗作用。方法:采用高脂饲料(HFD)诱导MASLD模型,并用不同剂量的WLS处理。监测体重和血脂,采用ELISA和RT-qPCR检测炎症反应。H&E染色评价组织病理变化。16S rRNA测序和LC-MS/MS分析肠道菌群组成和胆汁酸谱。粪便菌群移植(FMT)实验验证了WLS对肠道菌群的影响。结果:WLS治疗可减轻MASLD大鼠体重,改善血脂指标,抑制炎症和肝损害。FMT实验结果表明,移植经wls处理的供体粪便微生物群可调节受体大鼠肠道微生物组成,恢复胆汁酸代谢稳态。讨论:本研究表明WLS通过调节多种病理通路治疗MASLD。其改善脂质代谢和减轻肝脏炎症的作用与MASLD的病理生理机制一致,表明其具有直接的肝保护作用。WLS干预显著恢复了肠道菌群多样性,增加了有益菌的比例,抑制了潜在的有害菌属,纠正了生态失调。FMT实验进一步证实,肠道微生物在介导WLS的治疗效果中起着至关重要的作用。当将来自经wls处理的供体的微生物群移植到受体大鼠体内时,在代谢标志物、肝脏组织病理学和胆汁酸稳态方面观察到显著改善。总的来说,数据支持WLS通过以肠-肝轴为中心的多目标策略改善MASLD。结论:WLS可改善脂质代谢,减轻肝脏炎症,重塑肠道菌群,调节胆汁酸稳态,对MASLD具有有效的治疗作用。
{"title":"Wulingsan alleviates metabolic dysfunction-associated steatotic liver disease through regulating gut microbiota-bile acid axis","authors":"Junyu Luo ,&nbsp;Xiaowen Jin ,&nbsp;Mingyue Cui ,&nbsp;Hanyu He ,&nbsp;Jiabao Liao ,&nbsp;Weibo Wen ,&nbsp;Wenting Li ,&nbsp;Yongjun Cao","doi":"10.1016/j.prostaglandins.2026.107067","DOIUrl":"10.1016/j.prostaglandins.2026.107067","url":null,"abstract":"<div><h3>Background</h3><div>Metabolic dysfunction-associated Steatotic Liver Disease (MASLD) is closely linked to gut microbiota disorders and bile acid imbalance. Wulingsan (WLS) have shown promise in regulating these pathways, but its mechanism of action unclear. This study aimed to evaluate the therapeutic effect of WLS on the rat MASLD model from the perspectives of intestinal microbiota composition and bile acid homeostasis.</div></div><div><h3>Methods</h3><div>The MASLD model was induced by a high-fat diet (HFD) and treated with different doses of WLS. Body weight and serum lipid profiles were monitored, inflammation were assessed to ELISA and RT-qPCR. H&amp;E staining to evaluate histopathological changes. The 16S rRNA sequencing and LC-MS/MS analysis of gut microbiota composition and bile acid profiles. The fecal microbiota transplantation (FMT) experiment verified the effect of WLS on the gut microbiota.</div></div><div><h3>Results</h3><div>WLS treatment reduces the body weight of MASLD rats, improves lipid indicators, and inhibits inflammation and liver damage. The results of the FMT experiment indicated that transplantation of fecal microbiota from WLS-treated donors regulated the gut microbial composition and restored bile acid metabolic homeostasis in recipient rats.</div></div><div><h3>Discussion</h3><div>This study demonstrates that WLS treats MASLD by modulating multiple pathological pathways. Its effects in improving lipid metabolism and reducing hepatic inflammation align with the pathophysiological mechanisms of MASLD, indicating direct hepatoprotective actions. WLS intervention significantly restored gut microbiota diversity, increased the proportion of beneficial bacteria, suppressed potentially harmful bacterial genera, and corrected dysbiosis. FMT experiments further confirmed that gut microbes play a crucial role in mediating the therapeutic benefits of WLS. When microbiota from WLS-treated donors were transplanted into recipient rats, significant improvements were observed in metabolic markers, hepatic histopathology, and bile acid homeostasis. Collectively, the data support that WLS improves MASLD through a multi-targeted strategy centered on the gut-liver axis.</div></div><div><h3>Conclusion</h3><div>WLS has an effective therapeutic effect on MASLD by improving lipid metabolism, reducing liver inflammation, reshaping the intestinal microbiota and normalizing bile acid homeostasis.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"183 ","pages":"Article 107067"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147390934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resveratrol inhibits lipid deposition via JAML/Sirt1 pathway in podocytes 白藜芦醇通过JAML/Sirt1途径抑制足细胞脂质沉积。
IF 2.5 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-03-01 Epub Date: 2026-02-13 DOI: 10.1016/j.prostaglandins.2026.107061
Wei Gu , Xiaolong Li , Kunjie Zheng , Xiangtuo Wang , Guangyao Song
Lipid deposition plays a key role in the progression of diabetic kidney disease. We previously demonstrated that resveratrol modulates the junctional adhesion molecule-like protein (JAML)/Sirtuin 1 (Sirt1) pathway involved in lipid synthesis in the kidneys of mice under high-fat diet conditions, reducing lipid deposition. However, the specific mechanisms by which resveratrol affects palmitic acid (PA)-induced lipid accumulation and metabolism in podocytes remain unclear. In this study, we used mouse podocyte cell line 5 (MPC-5) to investigate the role of the JAML/Sirt1 pathway in de novo lipid synthesis. Resveratrol attenuated the abnormal expression of key components in the JAML/Sirt1 lipid synthesis pathway induced by PA in MPC-5 podocytes. Specifically, siRNA-mediated silencing of JAML increased Sirt1 expression in PA-treated MPC-5 podocytes, downregulating sterol regulatory element-binding protein-1, carbohydrate response element-binding protein, and adipose differentiation-related protein. In contrast, JAML overexpression reversed these effects. Resveratrol attenuated the metabolic abnormalities caused by JAML overexpression, suggesting that it inhibits intracellular lipid deposition in MPC-5 podocytes by regulating the JAML/Sirt1 pathway. Our findings provide new evidence that resveratrol improves lipid deposition in the kidneys and a new treatment strategy for renal diseases associated with lipid deposition in the kidneys.
脂质沉积在糖尿病肾病的进展中起关键作用。我们之前证明,白藜芦醇调节高脂饮食条件下小鼠肾脏中参与脂质合成的连接粘附分子样蛋白(JAML)/ Sirt1 (Sirt1)途径,减少脂质沉积。然而,白藜芦醇影响棕榈酸(PA)诱导的足细胞脂质积累和代谢的具体机制尚不清楚。在这项研究中,我们使用小鼠足细胞细胞系5 (MPC-5)来研究JAML/Sirt1通路在新生脂质合成中的作用。白藜芦醇可减弱PA诱导的MPC-5足细胞JAML/Sirt1脂质合成通路关键组分的异常表达。具体来说,sirna介导的JAML沉默增加了pa处理的MPC-5足细胞中Sirt1的表达,下调了固醇调节元件结合蛋白-1、碳水化合物反应元件结合蛋白和脂肪分化相关蛋白。相反,JAML过表达逆转了这些影响。白藜芦醇可减轻JAML过表达引起的代谢异常,提示其通过调节JAML/Sirt1通路抑制MPC-5足细胞胞内脂质沉积。我们的研究结果为白藜芦醇改善肾脏脂质沉积提供了新的证据,并为与肾脏脂质沉积相关的肾脏疾病提供了新的治疗策略。
{"title":"Resveratrol inhibits lipid deposition via JAML/Sirt1 pathway in podocytes","authors":"Wei Gu ,&nbsp;Xiaolong Li ,&nbsp;Kunjie Zheng ,&nbsp;Xiangtuo Wang ,&nbsp;Guangyao Song","doi":"10.1016/j.prostaglandins.2026.107061","DOIUrl":"10.1016/j.prostaglandins.2026.107061","url":null,"abstract":"<div><div>Lipid deposition plays a key role in the progression of diabetic kidney disease. We previously demonstrated that resveratrol modulates the junctional adhesion molecule-like protein (JAML)/Sirtuin 1 (Sirt1) pathway involved in lipid synthesis in the kidneys of mice under high-fat diet conditions, reducing lipid deposition. However, the specific mechanisms by which resveratrol affects palmitic acid (PA)-induced lipid accumulation and metabolism in podocytes remain unclear. In this study, we used mouse podocyte cell line 5 (MPC-5) to investigate the role of the JAML/Sirt1 pathway in <em>de novo</em> lipid synthesis. Resveratrol attenuated the abnormal expression of key components in the JAML/Sirt1 lipid synthesis pathway induced by PA in MPC-5 podocytes. Specifically, siRNA-mediated silencing of <em>JAML</em> increased Sirt1 expression in PA-treated MPC-5 podocytes, downregulating sterol regulatory element-binding protein-1, carbohydrate response element-binding protein, and adipose differentiation-related protein. In contrast, <em>JAML</em> overexpression reversed these effects. Resveratrol attenuated the metabolic abnormalities caused by <em>JAML</em> overexpression, suggesting that it inhibits intracellular lipid deposition in MPC-5 podocytes by regulating the JAML/Sirt1 pathway. Our findings provide new evidence that resveratrol improves lipid deposition in the kidneys and a new treatment strategy for renal diseases associated with lipid deposition in the kidneys.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"183 ","pages":"Article 107061"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146202501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cell metabolomics to reveal the mechanism of saponins and alkaloids on prostate inflammation via COX and LOX pathways 细胞代谢组学通过COX和LOX途径揭示皂苷和生物碱对前列腺炎症的作用机制。
IF 2.5 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-03-01 Epub Date: 2026-03-08 DOI: 10.1016/j.prostaglandins.2026.107066
Lili Liu , Lijuan Xue , Guiyue Hou , Jingxuan Zhang , Ling Tian , Xueqin Wang , Ronghua Dai
Inflammation initiates and progresses due to overexpression of the arachidonic acid cascade mediators. Cyclooxygenase (COX) and lipoxygenase (LOX) are considered to be the primary targets, and the aim of this study was to assess the anti- inflammatory activity of several herbal compounds as dual COX-LOX inhibitors on prostatic diseases. Compounds Timosaponin AⅡ, timosaponin AⅢ, berberine and demethyleneberberine were selected according to our previous studies. Human prostate cancer cells (PC-3) were cultured and the cell viability was detected by CCK-8 method at different concentrations. Ultra high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was applied to monitor the changes of AA metabolites after treatment. Western blot and qPCR were used to detect COX-2 and LOX-5 at protein and mRNA levels, respectively. Additionally, the levels of inflammatory factors (IL-6, IL-1β, TNF-α) in each group were detected by ELISA. After drug interference, 13 altered metabolites associated with the COX/LOX pathway, including PGE2, 5-HETE, LTB4, etc. were identified in cell medium. Quantitative metabolomics analysis showed that the candidate compounds could significantly decreased the concentrations of dual target related metabolites to varying degrees (P < 0.01). These compounds could also suppressed COX-2 and LOX-5 expression at the protein and mRNA levels simultaneously. Moreover, the levels of cytokine IL-6, IL-1β and TNF-α were also significantly reduced in the treated group compared to controls (P < 0.05 or P < 0.01). Our findings revealed the four active compounds were potential COX/LOX dual-target inhibitors, which inhibited a range of inflammatory responses by interfering with AA metabolism and down-regulating the levels of COX and LOX metabolites.
炎症的开始和发展是由于花生四烯酸级联介质的过度表达。环氧合酶(COX)和脂氧合酶(LOX)被认为是主要靶点,本研究的目的是评估几种草药化合物作为COX-LOX双抑制剂对前列腺疾病的抗炎活性。根据我们之前的研究选择化合物timmosaponin AⅡ、timmosaponin AⅢ、小檗碱和去亚甲基小檗碱。培养人前列腺癌细胞(PC-3),用CCK-8法检测不同浓度下的细胞活力。采用超高效液相色谱-串联质谱法(UPLC-MS/MS)监测处理后AA代谢物的变化。Western blot和qPCR分别检测COX-2和LOX-5蛋白和mRNA水平。ELISA法检测各组炎症因子(IL-6、IL-1β、TNF-α)水平。药物干扰后,在细胞培养基中鉴定出13种与COX/LOX通路相关的改变代谢物,包括PGE2、5-HETE、LTB4等。定量代谢组学分析表明,候选化合物可以不同程度地显著降低双靶标相关代谢物的浓度(P
{"title":"Cell metabolomics to reveal the mechanism of saponins and alkaloids on prostate inflammation via COX and LOX pathways","authors":"Lili Liu ,&nbsp;Lijuan Xue ,&nbsp;Guiyue Hou ,&nbsp;Jingxuan Zhang ,&nbsp;Ling Tian ,&nbsp;Xueqin Wang ,&nbsp;Ronghua Dai","doi":"10.1016/j.prostaglandins.2026.107066","DOIUrl":"10.1016/j.prostaglandins.2026.107066","url":null,"abstract":"<div><div>Inflammation initiates and progresses due to overexpression of the arachidonic acid cascade mediators. Cyclooxygenase (COX) and lipoxygenase (LOX) are considered to be the primary targets, and the aim of this study was to assess the anti- inflammatory activity of several herbal compounds as dual COX-LOX inhibitors on prostatic diseases. Compounds Timosaponin AⅡ, timosaponin AⅢ, berberine and demethyleneberberine were selected according to our previous studies. Human prostate cancer cells (PC-3) were cultured and the cell viability was detected by CCK-8 method at different concentrations. Ultra high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was applied to monitor the changes of AA metabolites after treatment. Western blot and qPCR were used to detect COX-2 and LOX-5 at protein and mRNA levels, respectively. Additionally, the levels of inflammatory factors (IL-6, IL-1β, TNF-α) in each group were detected by ELISA. After drug interference, 13 altered metabolites associated with the COX/LOX pathway, including PGE<sub>2</sub>, 5-HETE, LTB<sub>4</sub>, etc. were identified in cell medium. Quantitative metabolomics analysis showed that the candidate compounds could significantly decreased the concentrations of dual target related metabolites to varying degrees (<em>P</em> &lt; 0.01). These compounds could also suppressed COX-2 and LOX-5 expression at the protein and mRNA levels simultaneously. Moreover, the levels of cytokine IL-6, IL-1β and TNF-α were also significantly reduced in the treated group compared to controls (<em>P</em> &lt; 0.05 or <em>P</em> &lt; 0.01). Our findings revealed the four active compounds were potential COX/LOX dual-target inhibitors, which inhibited a range of inflammatory responses by interfering with AA metabolism and down-regulating the levels of COX and LOX metabolites.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"183 ","pages":"Article 107066"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147390931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resolvin E1 and Resolvin E2 suppress cyclooxygenase-2 expression through ubiquitin-proteasome-mediated degradation in human macrophage-like U937 cells 在人巨噬细胞样U937细胞中,Resolvin E1和Resolvin E2通过泛素蛋白酶体介导的降解抑制环氧化酶2的表达。
IF 2.5 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-03-01 Epub Date: 2026-02-16 DOI: 10.1016/j.prostaglandins.2026.107064
Ayaka Hamaguchi , Hayato Fukuda , Mizuki Watanabe , Koichi Fujiwara , Keijo Fukushima , Satoshi Shuto , Hiromichi Fujino
Inflammatory responses comprise a crucial defense mechanism against infection and injury. Prostanoids, including prostaglandin E2 (PGE2), are well-known to play important roles in the generation of inflammatory responses. However, their excessive or prolonged activation can cause tissue damage and drive the development of diseases. Resolvin E-series (RvEs), including RvE1, RvE2, and RvE3, are specialized pro-resolving mediators that actively promote the resolution of inflammation. Here, using human macrophage-like U937 cells, we show that RvE1 and RvE2, but not RvE3, suppressed protein expression of cyclooxygenase (COX)-2, an essential and inducible enzyme involved in prostanoid synthesis during the onset of inflammatory responses. Furthermore, the suppression of COX-2 protein expression by RvE1 and RvE2 was suggested to involve enhanced ubiquitin-proteasome-dependent degradation, resulting in the rapid reduction of PGE2 production by decreasing functional COX-2. This is the first reported evidence that RvEs exert pro-resolving effects on macrophage-associated COX-2/PGE2 signaling. Importantly, RvEs reduced COX-2 expression at the low concentration of 10 nM without affecting COX-1 expression. Thus, they may represent promising candidates for novel anti-inflammatory drugs with potentially fewer gastrointestinal side effects than exhibited by many nonsteroidal anti-inflammatory drugs.
炎症反应是抵抗感染和损伤的重要防御机制。前列腺素,包括前列腺素E2 (PGE2),在炎症反应的产生中起着重要作用。然而,它们的过度或长时间的激活会导致组织损伤并驱动疾病的发展。Resolvin e系列(RvEs)包括RvE1、RvE2和RvE3,是一种专门的促化解介质,可以积极促进炎症的消退。在这里,我们使用人巨噬细胞样U937细胞,我们发现RvE1和RvE2,而不是RvE3,抑制环氧化酶(COX)-2的蛋白表达,COX -2是炎症反应发生时参与前列腺素合成的一种必需的诱导酶。此外,RvE1和RvE2对COX-2蛋白表达的抑制可能与增强泛素-蛋白酶体依赖性降解有关,从而通过降低功能性COX-2导致PGE2生成的快速减少。这是首次报道RvEs对巨噬细胞相关COX-2/PGE2信号通路发挥促溶解作用的证据。重要的是,RvEs在低浓度10nM下降低了COX-2的表达,而不影响COX-1的表达。因此,与许多非甾体类抗炎药相比,它们可能代表有希望的新型抗炎药候选物,其胃肠道副作用可能更少。
{"title":"Resolvin E1 and Resolvin E2 suppress cyclooxygenase-2 expression through ubiquitin-proteasome-mediated degradation in human macrophage-like U937 cells","authors":"Ayaka Hamaguchi ,&nbsp;Hayato Fukuda ,&nbsp;Mizuki Watanabe ,&nbsp;Koichi Fujiwara ,&nbsp;Keijo Fukushima ,&nbsp;Satoshi Shuto ,&nbsp;Hiromichi Fujino","doi":"10.1016/j.prostaglandins.2026.107064","DOIUrl":"10.1016/j.prostaglandins.2026.107064","url":null,"abstract":"<div><div>Inflammatory responses comprise a crucial defense mechanism against infection and injury. Prostanoids, including prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), are well-known to play important roles in the generation of inflammatory responses. However, their excessive or prolonged activation can cause tissue damage and drive the development of diseases. Resolvin E-series (RvEs), including RvE1, RvE2, and RvE3, are specialized pro-resolving mediators that actively promote the resolution of inflammation. Here, using human macrophage-like U937 cells, we show that RvE1 and RvE2, but not RvE3, suppressed protein expression of cyclooxygenase (COX)-2, an essential and inducible enzyme involved in prostanoid synthesis during the onset of inflammatory responses. Furthermore, the suppression of COX-2 protein expression by RvE1 and RvE2 was suggested to involve enhanced ubiquitin-proteasome-dependent degradation, resulting in the rapid reduction of PGE<sub>2</sub> production by decreasing functional COX-2. This is the first reported evidence that RvEs exert pro-resolving effects on macrophage-associated COX-2/PGE<sub>2</sub> signaling. Importantly, RvEs reduced COX-2 expression at the low concentration of 10 nM without affecting COX-1 expression. Thus, they may represent promising candidates for novel anti-inflammatory drugs with potentially fewer gastrointestinal side effects than exhibited by many nonsteroidal anti-inflammatory drugs.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"183 ","pages":"Article 107064"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146220980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multiscale analysis of resolvin D1 biosynthesis and its neuroprotective role in intracerebral hemorrhage Resolvin D1生物合成及其在脑出血中的神经保护作用的多尺度分析。
IF 2.5 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-03-01 Epub Date: 2026-02-18 DOI: 10.1016/j.prostaglandins.2026.107063
Lv Xiaoyu , Zhang Ziyou , Liu Zhenlin , Li Zhuang , Sun Kai , Wang Siqi , Li Tong , Li Yunfei , Zhou Weixiu , Wang Yifan , Shi Chun , Zhang Bensi

Background

Intracerebral hemorrhage (ICH) is a destructive cerebrovascular disease, whose secondary injury can trigger severe neuroinflammatory responses. Resolvin D1 (RvD1), as an endogenous specific pro-resolving mediator, has been demonstrated to possess significant anti-inflammatory effects. However, how brain networks relate to RvD1 biosynthesis and the therapeutic potential of RvD1 in post-hemorrhagic repair processes within the brain remain unclear.

Methods

Serum RvD1 levels were measured at admission and discharge in 40 ICH patients, and their correlation with neurological functional outcomes was analyzed. Combining neuroimaging and Mendelian randomization, we investigated the association between brain network integrity and genetically predicted plasma RvD1 levels. Network pharmacology identified key targets, and an oxyhemoglobin-induced BV2 microglial model validated RvD1’s BDNF-dependent anti-inflammatory and anti-apoptotic effects.

Results

Serum RvD1 levels decreased from admission to discharge during recovery, with significant correlation between its changes and neurological improvement. Neuroimaging and MR analysis revealed that brain network integrity is significantly associated with genetically predicted plasma RvD1 levels, partially explaining interindividual prognostic variation. Mechanistically, RvD1 modulates microglial metabolism, alleviates oxidative stress, and promotes anti-inflammatory polarization involving the BDNF/AKT signaling network.

Conclusion

Genetically predicted plasma RvD1 levels correlate with macro-level brain network integrity while simultaneously promoting micro-level neural repair. This approach overcomes limitations of previous single-pathway or static indicator studies, offering novel biomarkers and intervention strategies with predictive and therapeutic potential for ICH.
背景:脑出血是一种破坏性的脑血管疾病,其继发性损伤可引发严重的神经炎症反应。溶解蛋白D1 (Resolvin D1, RvD1)是一种内源性特异性促溶解介质,具有显著的抗炎作用。然而,脑网络与RvD1生物合成的关系以及RvD1在脑出血后修复过程中的治疗潜力仍不清楚。方法:测定40例脑出血患者入院和出院时血清RvD1水平,并分析其与神经功能预后的相关性。结合神经影像学和孟德尔随机化,我们研究了脑网络完整性和遗传预测血浆RvD1水平之间的关系。网络药理学确定了关键靶点,氧血红蛋白诱导的BV2小胶质细胞模型验证了RvD1依赖bdnf的抗炎和抗凋亡作用。结果:恢复期血清RvD1水平从入院到出院均有所下降,其变化与神经系统改善有显著相关性。神经影像学和MR分析显示,脑网络完整性与遗传预测的血浆RvD1水平显著相关,部分解释了个体间的预后差异。机制上,RvD1通过BDNF/AKT信号网络调节小胶质细胞代谢,缓解氧化应激,促进抗炎极化。结论:基因预测血浆RvD1水平与宏观脑网络完整性相关,同时促进微观神经修复。该方法克服了以往单途径或静态指标研究的局限性,为脑出血提供了具有预测和治疗潜力的新型生物标志物和干预策略。
{"title":"Multiscale analysis of resolvin D1 biosynthesis and its neuroprotective role in intracerebral hemorrhage","authors":"Lv Xiaoyu ,&nbsp;Zhang Ziyou ,&nbsp;Liu Zhenlin ,&nbsp;Li Zhuang ,&nbsp;Sun Kai ,&nbsp;Wang Siqi ,&nbsp;Li Tong ,&nbsp;Li Yunfei ,&nbsp;Zhou Weixiu ,&nbsp;Wang Yifan ,&nbsp;Shi Chun ,&nbsp;Zhang Bensi","doi":"10.1016/j.prostaglandins.2026.107063","DOIUrl":"10.1016/j.prostaglandins.2026.107063","url":null,"abstract":"<div><h3>Background</h3><div>Intracerebral hemorrhage (ICH) is a destructive cerebrovascular disease, whose secondary injury can trigger severe neuroinflammatory responses. Resolvin D1 (RvD1), as an endogenous specific pro-resolving mediator, has been demonstrated to possess significant anti-inflammatory effects. However, how brain networks relate to RvD1 biosynthesis and the therapeutic potential of RvD1 in post-hemorrhagic repair processes within the brain remain unclear.</div></div><div><h3>Methods</h3><div>Serum RvD1 levels were measured at admission and discharge in 40 ICH patients, and their correlation with neurological functional outcomes was analyzed. Combining neuroimaging and Mendelian randomization, we investigated the association between brain network integrity and genetically predicted plasma RvD1 levels. Network pharmacology identified key targets, and an oxyhemoglobin-induced BV2 microglial model validated RvD1’s <em>BDNF-</em>dependent anti-inflammatory and anti-apoptotic effects.</div></div><div><h3>Results</h3><div>Serum RvD1 levels decreased from admission to discharge during recovery, with significant correlation between its changes and neurological improvement. Neuroimaging and MR analysis revealed that brain network integrity is significantly associated with genetically predicted plasma RvD1 levels, partially explaining interindividual prognostic variation. Mechanistically, RvD1 modulates microglial metabolism, alleviates oxidative stress, and promotes anti-inflammatory polarization involving the <em>BDNF</em>/<em>AKT</em> signaling network.</div></div><div><h3>Conclusion</h3><div>Genetically predicted plasma RvD1 levels correlate with macro-level brain network integrity while simultaneously promoting micro-level neural repair. This approach overcomes limitations of previous single-pathway or static indicator studies, offering novel biomarkers and intervention strategies with predictive and therapeutic potential for ICH.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"183 ","pages":"Article 107063"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146259036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digoxin-induced gut dysbiosis: Mechanistic links to prostaglandin dysregulation and lipid metabolic imbalance 地高辛诱导的肠道生态失调:前列腺素失调和脂质代谢失衡的机制联系。
IF 2.5 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-01-01 Epub Date: 2025-12-21 DOI: 10.1016/j.prostaglandins.2025.107055
Nila Ganamurali , Sarvesh Sabarathinam
Digoxin, a cardiac glycoside with established roles in heart failure and arrhythmia, increasingly exemplifies drug–microbiome–host interactions. Its bioavailability and efficacy are profoundly influenced by Eggerthella lenta–mediated reduction, producing inactive metabolites that reshape systemic physiology. Emerging evidence demonstrates that digoxin-induced gut dysbiosis perturbs arachidonic acid metabolism, altering cyclooxygenase-driven prostaglandin production and disrupting vascular tone and inflammatory homeostasis. These changes extend to lipid regulation, where reduced short-chain fatty acid production and bile acid derangements impair hepatic lipid utilization, promoting steatosis and metabolic dysfunction. This review integrates mechanistic insights into digoxin–microbiota interactions, prostaglandin pathway perturbation, and lipid imbalance, emphasizing their clinical significance and therapeutic implications for precision medicine in cardiovascular care.
地高辛是一种心脏糖苷,在心力衰竭和心律失常中有明确的作用,越来越多地成为药物-微生物-宿主相互作用的例证。它的生物利用度和功效受到卵ella lenta介导的还原的深刻影响,产生重塑系统生理的无活性代谢物。新出现的证据表明,地高辛诱导的肠道生态失调会扰乱花生四烯酸代谢,改变环氧化酶驱动的前列腺素产生,破坏血管张力和炎症稳态。这些变化延伸到脂质调节,其中短链脂肪酸生成减少和胆汁酸紊乱损害肝脏脂质利用,促进脂肪变性和代谢功能障碍。这篇综述整合了地高辛-微生物群相互作用、前列腺素通路扰动和脂质失衡的机制见解,强调了它们在心血管护理中的临床意义和治疗意义。
{"title":"Digoxin-induced gut dysbiosis: Mechanistic links to prostaglandin dysregulation and lipid metabolic imbalance","authors":"Nila Ganamurali ,&nbsp;Sarvesh Sabarathinam","doi":"10.1016/j.prostaglandins.2025.107055","DOIUrl":"10.1016/j.prostaglandins.2025.107055","url":null,"abstract":"<div><div>Digoxin, a cardiac glycoside with established roles in heart failure and arrhythmia, increasingly exemplifies drug–microbiome–host interactions. Its bioavailability and efficacy are profoundly influenced by <em>Eggerthella lenta</em>–mediated reduction, producing inactive metabolites that reshape systemic physiology. Emerging evidence demonstrates that digoxin-induced gut dysbiosis perturbs arachidonic acid metabolism, altering cyclooxygenase-driven prostaglandin production and disrupting vascular tone and inflammatory homeostasis. These changes extend to lipid regulation, where reduced short-chain fatty acid production and bile acid derangements impair hepatic lipid utilization, promoting steatosis and metabolic dysfunction. This review integrates mechanistic insights into digoxin–microbiota interactions, prostaglandin pathway perturbation, and lipid imbalance, emphasizing their clinical significance and therapeutic implications for precision medicine in cardiovascular care.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"182 ","pages":"Article 107055"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145820433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SREBF1 maintains the contractile phenotype of vascular smooth muscle cells via PPARγ signalling SREBF1通过PPARγ信号传导维持血管平滑肌细胞的收缩表型。
IF 2.5 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-01-01 Epub Date: 2025-12-16 DOI: 10.1016/j.prostaglandins.2025.107054
Xiaoying Chen , Huiling Jin , Guanyi Zheng

Background

Atherosclerosis is a complex chronic inflammatory disease. Although SREBF1 has been implicated in the regulation of atherosclerotic progression, its precise mechanisms remain incompletely understood.

Methods

The study constructed an in vitro model of atherosclerosis by exposing vascular smooth muscle cells (VSMCs) to oxidized low-density lipoprotein. The model was validated through inverted microscopy, quantitative polymerase chain reaction, and western blotting. The effects of SREBF1 on VSMC’s functions, including proliferation, migration, and clonogenic capacity, were assessed using Cell Counting Kit-8 assays, scratch wound healing assays, and colony formation assays, and western blotting following SREBF1 knockdown or overexpression. The PPARγ signalling pathway was further examined by western blotting and dual-luciferase reporter gene assay.

Results

The experimental results demonstrated that knockdown of SREBF1 significantly enhanced VSMC proliferation and migration while suppressing the expression of the two contractile markers SM22α and α-SMA. Mechanistic studies revealed that SREBF1 directly upregulated PPARγ transcriptional activity, activated PPARγ expression, and inhibited phosphorylated PPARγ expression. Notably, the addition of GW9662, a specific PPARγ signalling inhibitor, partially reversed the regulatory effects of SREBF1 overexpression on VSMC proliferation, migration, and phenotype.

Conclusion

This research found that SREBF1 maintains the contractile phenotype of VSMCs by activating PPARγ signalling, suggesting that SREBF1 may serve as a key molecule in ameliorating atherosclerosis.
背景:动脉粥样硬化是一种复杂的慢性炎症性疾病。尽管SREBF1参与了动脉粥样硬化进程的调控,但其确切机制仍不完全清楚。方法:将血管平滑肌细胞(VSMCs)暴露于氧化低密度脂蛋白环境下,建立动脉粥样硬化体外模型。通过倒置显微镜、定量聚合酶链反应和免疫印迹对模型进行验证。SREBF1对VSMC功能的影响,包括增殖、迁移和克隆生成能力,通过细胞计数试剂盒-8测定、划痕伤口愈合测定、菌落形成测定和SREBF1敲除或过表达后的western blotting来评估。采用western blotting和双荧光素酶报告基因试验进一步检测PPARγ信号通路。结果:实验结果表明,敲低SREBF1可显著增强VSMC的增殖和迁移,同时抑制两种收缩标志物SM22α和α-SMA的表达。机制研究表明,SREBF1直接上调PPARγ转录活性,激活PPARγ表达,抑制磷酸化的PPARγ表达。值得注意的是,加入特定的PPARγ信号抑制剂GW9662,部分逆转了SREBF1过表达对VSMC增殖、迁移和表型的调节作用。结论:本研究发现SREBF1通过激活PPARγ信号通路维持VSMCs的收缩表型,提示SREBF1可能是改善动脉粥样硬化的关键分子。
{"title":"SREBF1 maintains the contractile phenotype of vascular smooth muscle cells via PPARγ signalling","authors":"Xiaoying Chen ,&nbsp;Huiling Jin ,&nbsp;Guanyi Zheng","doi":"10.1016/j.prostaglandins.2025.107054","DOIUrl":"10.1016/j.prostaglandins.2025.107054","url":null,"abstract":"<div><h3>Background</h3><div>Atherosclerosis is a complex chronic inflammatory disease. Although SREBF1 has been implicated in the regulation of atherosclerotic progression, its precise mechanisms remain incompletely understood.</div></div><div><h3>Methods</h3><div>The study constructed an <em>in vitro</em> model of atherosclerosis by exposing vascular smooth muscle cells (VSMCs) to oxidized low-density lipoprotein. The model was validated through inverted microscopy, quantitative polymerase chain reaction, and western blotting. The effects of SREBF1 on VSMC’s functions, including proliferation, migration, and clonogenic capacity, were assessed using Cell Counting Kit-8 assays, scratch wound healing assays, and colony formation assays, and western blotting following SREBF1 knockdown or overexpression. The PPARγ signalling pathway was further examined by western blotting and dual-luciferase reporter gene assay.</div></div><div><h3>Results</h3><div>The experimental results demonstrated that knockdown of SREBF1 significantly enhanced VSMC proliferation and migration while suppressing the expression of the two contractile markers SM22α and α-SMA. Mechanistic studies revealed that SREBF1 directly upregulated PPARγ transcriptional activity, activated PPARγ expression, and inhibited phosphorylated PPARγ expression. Notably, the addition of GW9662, a specific PPARγ signalling inhibitor, partially reversed the regulatory effects of SREBF1 overexpression on VSMC proliferation, migration, and phenotype.</div></div><div><h3>Conclusion</h3><div>This research found that SREBF1 maintains the contractile phenotype of VSMCs by activating PPARγ signalling, suggesting that SREBF1 may serve as a key molecule in ameliorating atherosclerosis.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"182 ","pages":"Article 107054"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145782692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Signaling pathways shaping the field of lipidomics 形成脂质组学领域的信号通路
IF 2.5 3区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2026-01-01 Epub Date: 2025-12-10 DOI: 10.1016/j.prostaglandins.2025.107053
Ehsan Pashay Ahi , Andrew H. House
Lipidomics, the comprehensive study of cellular lipids and their roles in biological systems, has become a transformative tool across diverse fields of biology and medicine. Beyond its applications in studying metabolic disorders and cancer, lipidomics is gaining importance in areas such as developmental biology, ecology, and evolution, revealing critical insights into cellular processes and organismal adaptations. However, interpreting lipidomics data at the molecular level, particularly through the lens of signaling pathways, remains a challenge. Despite the central role of signaling pathways in regulating lipid metabolism and signaling, no comprehensive review has systematically compiled these pathways or explored their significance in lipidomics research. This review addresses this gap by providing a structured, catalogue-like overview of signaling pathways that regulate or are influenced by lipid signals. It includes pathways fundamental to lipid metabolism and related lipid-based biological processes, as well as emerging lipid-dependent mechanisms underlying energy balance, environmental adaptation, and developmental processes. Each pathway is briefly discussed in the context of its molecular roles in lipidomics and its potential impact on diverse research fields. By compiling this knowledge, the review serves as a guide for interpreting lipidomics data, identifying key pathways for targeted research, and bridging connections with other scientific disciplines. This structured approach promotes the integration of lipidomics into broader biological contexts, advancing our understanding of lipid-mediated processes and fostering innovation across multiple fields of study.
脂质组学是对细胞脂质及其在生物系统中的作用的综合研究,已成为跨越生物学和医学各个领域的变革工具。除了在研究代谢紊乱和癌症方面的应用外,脂质组学在发育生物学、生态学和进化等领域也越来越重要,揭示了对细胞过程和有机体适应的关键见解。然而,在分子水平上解释脂质组学数据,特别是通过信号通路的视角,仍然是一个挑战。尽管信号通路在调节脂质代谢和信号传导方面发挥着核心作用,但目前还没有全面的综述系统地整理这些通路或探讨它们在脂质组学研究中的意义。这篇综述通过提供一个结构化的、目录式的调控或受脂质信号影响的信号通路概述来解决这一空白。它包括脂质代谢的基本途径和相关的以脂质为基础的生物过程,以及能量平衡、环境适应和发育过程中新兴的脂质依赖机制。本文简要讨论了每种途径在脂质组学中的分子作用及其对不同研究领域的潜在影响。通过汇编这些知识,该综述可以作为解释脂质组学数据的指南,确定目标研究的关键途径,并与其他科学学科建立联系。这种结构化的方法促进了脂质组学与更广泛的生物学背景的整合,促进了我们对脂质介导过程的理解,并促进了跨多个研究领域的创新。
{"title":"Signaling pathways shaping the field of lipidomics","authors":"Ehsan Pashay Ahi ,&nbsp;Andrew H. House","doi":"10.1016/j.prostaglandins.2025.107053","DOIUrl":"10.1016/j.prostaglandins.2025.107053","url":null,"abstract":"<div><div>Lipidomics, the comprehensive study of cellular lipids and their roles in biological systems, has become a transformative tool across diverse fields of biology and medicine. Beyond its applications in studying metabolic disorders and cancer, lipidomics is gaining importance in areas such as developmental biology, ecology, and evolution, revealing critical insights into cellular processes and organismal adaptations. However, interpreting lipidomics data at the molecular level, particularly through the lens of signaling pathways, remains a challenge. Despite the central role of signaling pathways in regulating lipid metabolism and signaling, no comprehensive review has systematically compiled these pathways or explored their significance in lipidomics research. This review addresses this gap by providing a structured, catalogue-like overview of signaling pathways that regulate or are influenced by lipid signals. It includes pathways fundamental to lipid metabolism and related lipid-based biological processes, as well as emerging lipid-dependent mechanisms underlying energy balance, environmental adaptation, and developmental processes. Each pathway is briefly discussed in the context of its molecular roles in lipidomics and its potential impact on diverse research fields. By compiling this knowledge, the review serves as a guide for interpreting lipidomics data, identifying key pathways for targeted research, and bridging connections with other scientific disciplines. This structured approach promotes the integration of lipidomics into broader biological contexts, advancing our understanding of lipid-mediated processes and fostering innovation across multiple fields of study.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"182 ","pages":"Article 107053"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145738585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Prostaglandins & other lipid mediators
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1